Selected research
Industry Research
Daclatasvir Industry Research Report 2026
Market perspective
The global Daclatasvir market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Daclatasvir is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Daclatasvir is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Daclatasvir is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Daclatasvir include Abbott, Mylan, Bristol-Myers Squibb, Zydus Cadila, Torrent Pharmaceuticals, Natco Pharma, Hetero Drugs, Emcure Pharmaceuticals and Dr Reddy's Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Daclatasvir market in terms of revenue (US$ million) and, where applicable, sales volume (k pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Daclatasvir Market by Company
Abbott
Mylan
Bristol-Myers Squibb
Zydus Cadila
Torrent Pharmaceuticals
Natco Pharma
Hetero Drugs
Emcure Pharmaceuticals
Dr Reddy's Laboratories
Cipla
Biocon
Daclatasvir Segment by Type
30mg Tables
60mg Tables
Daclatasvir Segment by Application
Hepatitis C Virus (HCV) Genotype 4
Hepatitis C Virus (HCV) Genotype 3
Hepatitis C Virus (HCV) Genotype 1
Daclatasvir Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Daclatasvir market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Daclatasvir and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Daclatasvir.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Daclatasvir manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Daclatasvir by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Daclatasvir in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 30mg Tables
- 60mg Tables
Applications
- Hepatitis C Virus (HCV) Genotype 4
- Hepatitis C Virus (HCV) Genotype 3
- Hepatitis C Virus (HCV) Genotype 1
Companies covered
- Abbott
- Mylan
- Bristol-Myers Squibb
- Zydus Cadila
- Torrent Pharmaceuticals
- Natco Pharma
- Hetero Drugs
- Emcure Pharmaceuticals
- Dr Reddy's Laboratories
- Cipla
- Biocon
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Daclatasvir Market Size (2021-2032)
- 2.2.2 Global Daclatasvir Sales (2021-2032)
- 2.2.3 Global Daclatasvir Market Average Price (2021-2032)
- 2.3 Daclatasvir by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 30mg Tables
- 2.3.3 60mg Tables
- 2.4 Daclatasvir by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hepatitis C Virus (HCV) Genotype 4
- 2.4.3 Hepatitis C Virus (HCV) Genotype 3
- 2.4.4 Hepatitis C Virus (HCV) Genotype 1
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Daclatasvir Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Daclatasvir Sales (k pcs) of Manufacturers (2021-2026)
- 3.3 Global Daclatasvir Revenue of Manufacturers (2021-2026)
- 3.4 Global Daclatasvir Average Price by Manufacturers (2021-2026)
- 3.5 Global Daclatasvir Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Daclatasvir, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Daclatasvir, Product Type & Application
- 3.8 Global Manufacturers of Daclatasvir, Established Date
- 3.9 Global Daclatasvir Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abbott
- 4.1.1 Abbott Company Information
- 4.1.2 Abbott Business Overview
- 4.1.3 Abbott Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abbott Daclatasvir Product Portfolio
- 4.1.5 Abbott Recent Developments
- 4.2 Mylan
- 4.2.1 Mylan Company Information
- 4.2.2 Mylan Business Overview
- 4.2.3 Mylan Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Mylan Daclatasvir Product Portfolio
- 4.2.5 Mylan Recent Developments
- 4.3 Bristol-Myers Squibb
- 4.3.1 Bristol-Myers Squibb Company Information
- 4.3.2 Bristol-Myers Squibb Business Overview
- 4.3.3 Bristol-Myers Squibb Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bristol-Myers Squibb Daclatasvir Product Portfolio
- 4.3.5 Bristol-Myers Squibb Recent Developments
- 4.4 Zydus Cadila
- 4.4.1 Zydus Cadila Company Information
- 4.4.2 Zydus Cadila Business Overview
- 4.4.3 Zydus Cadila Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Zydus Cadila Daclatasvir Product Portfolio
- 4.4.5 Zydus Cadila Recent Developments
- 4.5 Torrent Pharmaceuticals
- 4.5.1 Torrent Pharmaceuticals Company Information
- 4.5.2 Torrent Pharmaceuticals Business Overview
- 4.5.3 Torrent Pharmaceuticals Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Torrent Pharmaceuticals Daclatasvir Product Portfolio
- 4.5.5 Torrent Pharmaceuticals Recent Developments
- 4.6 Natco Pharma
- 4.6.1 Natco Pharma Company Information
- 4.6.2 Natco Pharma Business Overview
- 4.6.3 Natco Pharma Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Natco Pharma Daclatasvir Product Portfolio
- 4.6.5 Natco Pharma Recent Developments
- 4.7 Hetero Drugs
- 4.7.1 Hetero Drugs Company Information
- 4.7.2 Hetero Drugs Business Overview
- 4.7.3 Hetero Drugs Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hetero Drugs Daclatasvir Product Portfolio
- 4.7.5 Hetero Drugs Recent Developments
- 4.8 Emcure Pharmaceuticals
- 4.8.1 Emcure Pharmaceuticals Company Information
- 4.8.2 Emcure Pharmaceuticals Business Overview
- 4.8.3 Emcure Pharmaceuticals Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Emcure Pharmaceuticals Daclatasvir Product Portfolio
- 4.8.5 Emcure Pharmaceuticals Recent Developments
- 4.9 Dr Reddy's Laboratories
- 4.9.1 Dr Reddy's Laboratories Company Information
- 4.9.2 Dr Reddy's Laboratories Business Overview
- 4.9.3 Dr Reddy's Laboratories Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Dr Reddy's Laboratories Daclatasvir Product Portfolio
- 4.9.5 Dr Reddy's Laboratories Recent Developments
- 4.10 Cipla
- 4.10.1 Cipla Company Information
- 4.10.2 Cipla Business Overview
- 4.10.3 Cipla Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Cipla Daclatasvir Product Portfolio
- 4.10.5 Cipla Recent Developments
- 4.11 Biocon
- 4.11.1 Biocon Company Information
- 4.11.2 Biocon Business Overview
- 4.11.3 Biocon Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Biocon Daclatasvir Product Portfolio
- 4.11.5 Biocon Recent Developments
5 Global Daclatasvir Market Scenario by Region
- 5.1 Global Daclatasvir Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Daclatasvir Sales by Region: 2021-2032
- 5.2.1 Global Daclatasvir Sales by Region: 2021-2026
- 5.2.2 Global Daclatasvir Sales by Region: 2027-2032
- 5.3 Global Daclatasvir Revenue by Region: 2021-2032
- 5.3.1 Global Daclatasvir Revenue by Region: 2021-2026
- 5.3.2 Global Daclatasvir Revenue by Region: 2027-2032
- 5.4 North America Daclatasvir Market Facts & Figures by Country
- 5.4.1 North America Daclatasvir Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Daclatasvir Sales by Country (2021-2032)
- 5.4.3 North America Daclatasvir Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Daclatasvir Market Facts & Figures by Country
- 5.5.1 Europe Daclatasvir Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Daclatasvir Sales by Country (2021-2032)
- 5.5.3 Europe Daclatasvir Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Daclatasvir Market Facts & Figures by Country
- 5.6.1 Asia Pacific Daclatasvir Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Daclatasvir Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Daclatasvir Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Daclatasvir Market Facts & Figures by Country
- 5.7.1 South America Daclatasvir Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Daclatasvir Sales by Country (2021-2032)
- 5.7.3 South America Daclatasvir Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Daclatasvir Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Daclatasvir Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Daclatasvir Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Daclatasvir Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Daclatasvir Sales by Type (2021-2032)
- 6.1.1 Global Daclatasvir Sales by Type (2021-2032) & (k pcs)
- 6.1.2 Global Daclatasvir Sales Market Share by Type (2021-2032)
- 6.2 Global Daclatasvir Revenue by Type (2021-2032)
- 6.2.1 Global Daclatasvir Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Daclatasvir Revenue Market Share by Type (2021-2032)
- 6.3 Global Daclatasvir Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Daclatasvir Sales by Application (2021-2032)
- 7.1.1 Global Daclatasvir Sales by Application (2021-2032) & (k pcs)
- 7.1.2 Global Daclatasvir Sales Market Share by Application (2021-2032)
- 7.2 Global Daclatasvir Revenue by Application (2021-2032)
- 7.2.1 Global Daclatasvir Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Daclatasvir Revenue Market Share by Application (2021-2032)
- 7.3 Global Daclatasvir Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Daclatasvir Value Chain Analysis
- 8.1.1 Daclatasvir Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Daclatasvir Production Mode & Process
- 8.2 Daclatasvir Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Daclatasvir Distributors
- 8.2.3 Daclatasvir Customers
9 Global Daclatasvir Analyzing Market Dynamics
- 9.1 Daclatasvir Industry Trends
- 9.2 Daclatasvir Industry Drivers
- 9.3 Daclatasvir Industry Opportunities and Challenges
- 9.4 Daclatasvir Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst